Expertise in
3
conditions

Holger N. Lode

Ferdinand Sauerbruch Str, 
Greifswald, MV, DE 
Expertise in
3
conditions
Ferdinand Sauerbruch Str, 
Greifswald, MV, DE 
OverviewLocationsClinical Research

Overview

Holger Lode practices in Greifswald, Germany. Mr. Lode is highly rated in 3 conditions, according to our data. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Ewing Sarcoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 98 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Ferdinand Sauerbruch Str, Greifswald, MV 17475, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide, Methotrexate, Prednisolone, Vincristine
Study Phase: Phase 3
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Enrollment Status: Completed
Publish Date: December 08, 2023
Intervention Type: Drug
Study Drug: ch14.18/CHO
Study Phase: Phase 2
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
Enrollment Status: Unknown
Publish Date: July 14, 2020
Intervention Type: Drug
Study Drugs: ch14.18/CHO, Aldesleukin, Isotretinoin
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

98 Total Publications

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.
Journal: Cancers
Published: July 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lode's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile